Stevens-Johnson Syndrome After Armodafinil Use

We present the case of a 21-year-old woman in whom Stevens-Johnson syndrome (SJS) developed after initiation of armodafinil. Although this rare and life-threatening reaction is listed on armodafinil's label, no cases have been reported in the literature. This case, in addition to an update of the drug's label after post-marketing research, both support the link between armodafinil and SJS. Providers should maintain a high clinical suspicion for SJS when starting therapy to minimize associated morbidity and mortality by discontinuing armodafinil at the onset of first symptoms.Citation:Holfinger S, Roy A, Schmidt M. Stevens-Johnson syndrome after armodafinil use.J Clin Sleep Med. 2018;14(5):885–887.
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Source Type: research